Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 33
BPC-157 personal reviews: what they show
Personal peptide reviews name doses and outcomes but lack controls and verified purity. Here is how to read them against actual BPC-157 data.
Is BPC-157 prohibited in sport? WADA rules
BPC-157 is banned under S0 of the WADA Prohibited List. Here is how the rule works, what USADA enforces, and what athletes need to know.
How BPC-157 works: a plain-English guide
BPC-157 appears to promote tissue repair in rodents through angiogenesis and nitric-oxide signalling. Here is what the preclinical data shows.
BPC-157 dosing: what the studies used
No validated human dose for BPC-157 exists. The 200 to 500 mcg range quoted online is an allometric extrapolation from rodent injury models, not clinical data.
Is BPC-157 legal? Status by country
BPC-157 is not approved for human use in any country we cover. Here is the regulatory status across the US, EU, and UK as of mid-2026.
What is BPC-157? A plain-English explainer
BPC-157 is a synthetic peptide from human gastric juice studied in rodents for tissue repair. No controlled human trial exists, and it is not approved anywhere.
Semaglutide vs tesamorelin compared
Semaglutide and tesamorelin are both FDA-approved peptides, but their regulatory paths, evidence bases and grey-market exposure could not be more different.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Low-dose semaglutide cuts weight in HARMONY
The HARMONY cohort from China reports 9.9% mean weight loss at 24 weeks on semaglutide 0.5 or 1.0 mg weekly, below the 2.4 mg obesity dose.